[1] TAO Q, LIANG PS.Evolution of diagnostic criteria for Sjögren's syndrome[J]. J Prev Treat Stom Dis(口腔疾病防治), 2019, 27(5): 273-278. [2] HUANG MJ, WANG JC, SUN L, et al.Sjgren's syndrome compl-icated by pneumocystis pneumonia: a case report and literature review[J]. Journal of Tropical Medicine(热带医学杂志), 2010, 10(10): 1193-1195. [3] SUN GL, LI LJ, ZHANG L, et al.Prognostic risk factors of pneumocystis pneumoniae with long-term glucocorticoid users[J]. Chin J Pract Intern Med(中国实用内科杂志), 2018, 38(10): 945-948. [4] HE XQ, SHEN YZ.Research progress in the diagnosis and treatment of Pneumocystis pneumonia[J]. Chin J Mycol(中国真菌学杂志), 2018, 13(4): 247-251. [5] KIM T, HONG HL, LEE YM, et al.Is caspofungin really an effective treatment for Pneumocystis jirovecii pneumonia in immunocompromised patients without human immunodeficiency virus infection? Experiences at a single center and a literature review[J]. Scandinavian Journal of Infectious Diseases, 2013, 45(6): 484-488. [6] XU LT, LI HH, ZHANG JH, et al.Advances in research on medicine therapy in treating Pneumocystis carinii pneumonia[J]. Journal of Lanzhou University(Medical Sciences)[兰州大学学报(医学版)], 2017, 43(2): 66-70. [7] CHEN XQ, JIN YY, TANG G.Newly edited pharmacology(新编药物学)[M]. 18th Ed.Beijing: People's Medical Publishing House,2018. [8] DORN JM, ALPERN M, MCNULTY C, et al.Sulfonamide drug allergy[J]. Curr Allergy Asthma Rep, 2018, 18(2): 38. [9] LI DK, SENG RY.Therapeutic Guidelines: Antibiotic[M]. 15th Ed.Beijing: Chemical Industry Publishers, 2018. [10] JOSEPH B, PRYOR AJ, OLYAEI DK, et al.Sulfonamide desensit-ization in solid organ transplant recipients: a protocol-driven approach during the index transplant hospitalization[J]. Transpl Infect Dis, 2019(21): e13191. [11] YUAN L, QIU XH, ZHAO TT, et al.Analysis of glucocorticoid applic-ation in a case of non- HIV complicated with severe pneumocystis pneumonia[J]. Chinese Journal of Clinical Rational Drug Use(临床合理用药杂志), 2019, 12(6A): 162-163. [12] WANG J, MENG XM, DONG P.Analysis of adverse drug reactions during therapy in 186 AIDS patients in our hospital[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(6): 364-373. [13] CHANG HM, TSAI HC, LEE SS, et al.High daily doses of trimet-hoprim/ sulfamethoxazole are an independent risk factor for adverse reactions in patients with Pneumocystis pneumonia and AIDS[J]. J Chin Med Assoc, 2016, 79(6): 314-323. [14] MA XJ, XU YC, LIU ZY.Diagnosis and Treatment of Infectious Diseases(传染病的诊断和治疗)[M]. 2nd ed. Beijing: Scientific and Technical Docume-ntation Press, 2016. [15] MASCHMEYER G, HELWEG LARSEN J, PAGANO L, et al.ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients[J]. J Antimicrob Chemother, 2016, 71(9): 2405-2413. [16] MILLER RF, HUANG L, WALZER PD.Pneumocystis pneumonia associated with human immuno deficiency virus[J]. Clin Chest Med, 2013, 34(2): 229-241. [17] KAPLAN JE, BENSON C, HOLMES KK, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health,the HIV Medicine Association of the Infectious Diseases Society of America[J]. MMWR Recomm Rep, 2009, 58(RR-4): 1-207, E1-E4. |